Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: gfp927z who wrote (1315)	11/25/2004 9:39:59 AM
From: Clarksterh	Respond to of 1386

For the Phase 2 TBI study, did Pharmos release the actual data / detailed summary of the data (one that was more detailed than their press release)? Yes. Sort of. They put out a paper combining 2 of the 3 arms. See the thread below for discussions of that paper and their retrospective culling of data. Was the Phase 2 powered to show statistical significance? A Phase II has a different purpose - to work through the bugs and determine how to size the phase iii. I don't really think they knew what they would find coming out of Phase II. Also, in the Phase 3, does anyone know the % level of improvement they'll need in order to show statistical significance for the various endpoints? Good question. 800+ patients is a lot. I suspect they could find even a 1/2 GOSE category improvement with stat sig, but I haven't worked the numbers. BTW - first read your questions as being inre the P II CABG. But updated this post to correct for my misread. Clark